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C O R E T VA S A 54 ( 2012 ) e1 –e2EditorialFirst issue of new Cor et Vasa published by new PublisherThe official journal of the Czech Society of Cardiology is at the
beginning of a new era – since January 1st, 2012 we have a
new publisher – Elsevier, well-recognized among scientific
and medical communities in the world. First issue of the year
2012, which you have in front of you, contains 13 articles
altogether: five original papers, two review articles, three case
reports, one historical comment and two letters to the editor.
Two papers are focusing on acute coronary syndromes
(ACS). First one is dealing with patients with high risk of acute
myocardial infarction (AMI) – those are the patients with AMI
caused by left main (LM) coronary artery disease – acute
occlusion or unstable critical stenosis of LM coronary artery
[1]. Other high risk groups with AMI include elderly patients
or patients with critical coronary pathology (for instance last
remaining coronary artery occlusion) or patients with signs of
acute heart failure. An early invasive strategy is highly
recommended in this group of patients. Even emergent
percutaneous coronary intervention with angiographic suc-
cess rate 72% is followed by a very high mortality rate – 25,8%
– in patients with acute LM occlusion.
Second, review article is focusing on recent developments
of antiplatelet therapy in ACS [2]. First one discussed is a third
generation thienopyridine – prasugrel, second one is ticagre-
lor – direct acting inhibitor of P2Y12 receptor. Both drugs have
been already evaluated in patients with ACS in randomized
clinical studies [3,4]. These studies showed that prasugrel
with aspirin was superior to clopidogrel with aspirin, as well
as that ticagrelor was superior to clopidogrel. These results
‘‘pushed’’ ahead evaluation of genetic variations of cyto-
chrome P450 2C19 and polymorphisms of P-glycoprotein,
which can affect clopidogrel or prasugrel transport and
efficacy. Results of genetic studies and platelet reactivity
testing are discussed in this article and it can be concluded
that their widespread use is currently not recommended in
clinical practice. On the other hand, we have enough evidence
that prasugrel and ticagrelor are potent drugs, which may
replace clopidogrel in the near future—recent guidelines of
European Society of Cardiology already recommend these
drugs as first line treatment [5]. The important issue is still
their price, substantially higher than with clopidogrel. But
cost analysis which was performed in TRITON-TIMI 38 Trial
showed that at a median 14,7 months follow-up average total
costs were US$ 228 lower with prasugrel compared toclopidogrel, mainly due to a lower rate of rehospitalisation
with prasugrel [6]. What is necessary to remember is the fact
that the use of very intense anti-platelet therapy needs a
serious consideration of risk/benefit ratio. We can expect that
future randomized trials investigating the role of antiplatelet
therapy guided by P2Y12 reactivity will provide new data
which will help in the use of therapeutic interventions for
patients with ACS.
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